Sanne Fournier Wendes-Enfermedades transmitidas por vectores
•
1 like•89 views
El 12 de mayo de 2017 celebramos en la Fundación Ramó Areces una jornada con IS Global y Unitaid sobre enfermedades transmitidas por vectores, como la malaria, entre otras.
Recommended
More Related Content
What's hot
What's hot (20)
Similar to Sanne Fournier Wendes-Enfermedades transmitidas por vectores
Similar to Sanne Fournier Wendes-Enfermedades transmitidas por vectores (20)
More from Fundación Ramón Areces
More from Fundación Ramón Areces (20)
Recently uploaded
Recently uploaded (20)
Sanne Fournier Wendes-Enfermedades transmitidas por vectores
- 1. Connecting Innovation to the Global Response Sanne Fournier-Wendes Thursday, 11 May2017
- 2. Agenda 2 How Unitaid operates New Strategy 2017-2021 & Call for Proposals
- 3. Agenda 3 How Unitaid operates New Strategy 2017-2021 & Call for Proposals
- 4. Upstream SystemsGovernments & Partners Innovation & Availability Devices Supply & Delivery Medicines Quality Projects with grantees Demand & Adoption Affordability Unitaid connects the upstream to the downstream HIV/AIDS Tuberculosis Malaria Downstream PDPs BMGFIndustryAcademia Others Grand Challenges … 4
- 5. Maximize the effectiveness of the global health response better health products catalyzing equitable access Our mission by to
- 6. Unitaid plays a role at 3 critical moments Objectives Innovation ScalabilityAccess Moment 2 Product is adopted Moment 3 Product is scaled-up Moment 1 Product is availableProductcoverage Maximize the effectiveness of the global health response... ... by catalyzing equitable access... ... to better health products 66
- 7. Agenda 7 How Unitaid operates New Strategy 2017-2021 & Call for proposals
- 8. Underpinned by: - Disease narratives - Thematic narrative RMNCH - Specific approaches Unitaid’s Strategy 2017-2021 8 Approved by EB in Dec 2016 More integrated approach to health HIV/AIDS (incl. co-infections), TB & malaria
- 9. Unitaid well placed in global health response 9
- 10. Translating global goals into concrete projects 1010
- 11. Anticipate upstream innovation Ensure readiness to scale up, including funding Anticipate and respond to country needs Partner engagement is key through entire process 1111
- 12. Ex: Next Generation Indoor Residual Spray (NgenIRS) IVCC 2016 – 2020 US$ 65.1 Improving affordability of new insecticides for resistance management Lead Grantee Grant Period Grant Value Grant Impact 50m people, 16 African countries Target Coverage 1212
- 13. 13 NGENIRS project overview High price Low uptake/ small market Weak forecast /long lead times One supplier Weak impact/ CE evidence Reduce price Copay- ment: ↑ uptake Forecast &under- write demand Multiple Suppliers Build impact/ CE evidence Key challenges Multi-pronged intervention 13
- 14. Cross- cutting Unitaid Malaria Grant Portfolio 14 Project Grantee Grant value ACCESS-SMC Malaria Consortium US$ 67.4m Global and National Quality Control For mRDTs FIND US$ 9.4m Next Generation Indoor Residual Spray (NgenIRS) IVCC US$ 65.1m ACTwatch 2 PSI US$ 2.8m Preventive treatment in pregnant women JHPIEGO US$ 49.5m Treatment of severe malaria CHAI US$ 19.1m Supply side interventions MMV US$ 3.4m Medicines Pre-Qualification WHO PQ US$ 33.7m Diagnostics Pre-Qualification WHO PQ US$ 10.5m RTS,S Pilot Implementation Programme WHO US$ 13.2m Innovative vector control tools TBD TBD Active in 2017 Under dev’t Just approved Call for Proposals 14
- 15. Call for Proposals 15 New-insecticide-based tools and/or application methods 15 Call for Proposals for interventions aimed at accelerating the availability of innovative vector control tools Late stage product development: • Large-scale field trials • Market entry preparatory activities New tools not based on insecticides
- 17. Unitaid’s current Areas for Intervention 17 TB Malaria HCV HIV Scale-up of PrEP & linkage to test Adult antiretroviral therapy improvement Preventive treatment in pregnant women Treatment of severe malaria Innovative vector control tools Simple, rapid diagnosis of HCV Preventive TB treatment Scale-up of better TB treatment in children Better, shorter treatment for MDR TB Call for Proposals 17
Editor's Notes
- UNITAID's clear positioning is as an organization that connects upstream innovation with the downstream response to the 3 diseases If we start with the downstream, there are many partners involved in scaling up access to health products, including countries themselves. We recognize that there are partners that have a much bigger footprint for scale up, incl GF and PMI. UNITAID is not a scale up organization, we help scale up partners maximize the efficicency of the response by using innovation to do more with less. On the same token. Many partners in the upstream that are working on innovation. that fund R&D, incl early stage. The list of partners is not exhaustive. UNITAID's role is to act as a hinge between the uprstream and downstream. Innovation reach the ppl who may need it the most Feedback loop - that we are in touch with our partners procuring, delivering HPs, can flag particular needs of ppl living in LMICs and provide feed back to developers CLICK We do this by identifiyng key barriers limiting innovations in medicines, devices and systems from reaching the global response for scale up. These can include barriers along the value chain. For example, adapted health products such as paediatric formulations may not be available on the market, or they may be too expensive for patients or country programs to use them. These products may be competing with suboptimal or poor quality alternatives, leading to low demand which further exacerbates high prices. We aim to resolve these barriers through targeted projects that we undertake with grantees.
- The way we look at it is that our mission corresponds to 3 key moments in the product lifecycle. CLICK Maximizing effectiveness of the GH response speaks to the moment at which a product is scaled up. This is the end goal for UTD – want to see a product avail, adopted and scaled up. CLICK If we work backwards, in order to do this, need to have access issues resolved for product to be adopted. This corresponds to the moment at which we have product adoption. CLICK Work backwards further, need to ensure that better health products are actually coming to the market. CLICK Our mission statement corresponds to these 3 moments. UNITAID invests in moments 1 an 2, and creates the necessary conditions for moment 3. but we don not fund scale up directly. These 3 moments therefore correspond to 3 strategic objs that underpin this mission: Innovation, Access and Scalability.
- Specific approaches (e.g. approach to IP)
- Unitaid’s strategic framework positions Unitaid as a unique player in the global health response. Mission: Maximize effectiveness of the global health response by catalysing equitable access to better health products 3 Strategic Objectives 4 Investment Commitments
- Key elements of Unitaid’s operating model include: surveying and identifying areas of need in the global response; inviting and selecting potential ideas to help close gaps; developing grants; disbursing funds and implementing grants, including transitioning to other sources of funding.
- 6 key partners: Countries, civil society, technical partners, private sector, funding partners, implementing partners Engaging with all the partners through the process allow Unitaid to: 1) anticipate and respond to country needs, 2) anticipate upstream innovation, 3) Ensure readiness to scale-up (incl. funding)
- As an example of how UNITAID connects upstream and dowwnsteam – NGENIRS. We are now 1.5 years into this grant. This US $65.1m initiative with IVCC, US President’s Malaria Initiative, Abt Associates, PATH and the Global Fund is supporting countries to obtain new and effective IRS insecticides. The project will make new products available at lower prices and facilitate the market introduction of new insecticides. Through this project, UNITAID and IVCC will catalyse the availability of alternative insecticides that have better efficacy and can support resistance management. Over four years, the project aims to protect as many as 50m people from malaria in 16 African countries. The overall impact of the grant is to create a more sustainable market for next-generation IRS products. This should contribute to bringing back IRS to historical coverage levels, and mitigating resistance to key insecticides. Over the long term, this will help to prevent more malaria cases, thereby saving lives and averting treatment costs. --- In 2016 3GIRS procurement accounted for 40% of total IRS in project countries with approximately 6 million people in Ethiopia, Mali, Rwanda and Zambia protected against malaria. This resulted in about 60% more people protected than would be possible without co-payment; A total of 678,569 bottles of Actellic®300CS (AC) delivered and IRS operations completed in year 1 countries, namely; Ethiopia, Mali, Rwanda and Zambia; In 2017, in partnership with programs funded by the U.S. President’s Malaria Initiative and the Global Fund, NgenIRS is expected to protect approximately 19.8 million people in 12 countries, up from the current 14 million in 4 countries. The project also aims to facilitate the introduction of 2-3 new insecticides into the market by 2020.
- Project aims to address a series of related and reinforcing challenges: high price of new product limits uptake and market remains nascent. As market size is small price does not decrease due to lack of economies of scale. Price is also high due to poor forecasting (and last minute changes to orders) which increases supplier risk, and a lack of competition. Finally, countries motivation to purchase a higher- priced product is limited by a lack of robust data to show its impact and CE. Summary of project interventions: Commodity co-payment to enable or expand 3GIRS coverage, leveraging partner countries existing investment from PMI or GF to grow the marketplace for 3GIRS products by 5-10 fold. The project will increase the capacity of countries to forecast demand more accurately and integrate into a global forecast. forecast guarantee and use an underwriting fund to absorb the risks. Increase the number of suppliers and variety of products with different active ingredients in 3GIRS formulations from 1 to 3. Generate sustainable demand through implementation research to establish and disseminate evidence of impact and cost-effectiveness of 3GIRS products. Negotiate reductions in price, reflecting this larger, more stable and more competitive market.
- RTS, S not approved by Board yet – not a result of call for proposal
- I am pleased to announce that today Unitaid is launching a new call for proposals for interventions aimed at accelerating the availability of innovative vector control tools. Late stage product development 2 categories: New insecticide-based tools (excl. new LLINs and new insecticides/equipment for IRS) New tools not based on insecticides (e.g. biological control methods, endectocidal chemotherapeutic agents, pull-push systems)